---
title: "Targeted Therapy and the Resistance That Follows It"
description: "A drug aimed at a driver works for as long as the driver is required and the target is unchanged. This stop works through the routes back: mutation of the target, bypass signalling, and selection of a"
canonical: https://lightmysky.com/learn/science/targeted-therapy-and-the-resistance-that-follows-it-mt_HrU1DfZhGz
source: https://lightmysky.com/learn/science/targeted-therapy-and-the-resistance-that-follows-it-mt_HrU1DfZhGz.md
retrieved: 2026-09-12
---

> **Agent view.** This is the Markdown twin of the page, for tools and assistants.
> When to use this site, and the call that answers each job: https://lightmysky.com/agent-instructions.md
> API description (OpenAPI 3.1): https://lightmysky.com/openapi.json · Authentication: https://lightmysky.com/auth.md
> Pricing: https://lightmysky.com/pricing.md · Catalog: https://lightmysky.com/llms.txt · Full catalog: https://lightmysky.com/llms-full.txt
> Every machine-readable file on this domain: https://lightmysky.com/.well-known/ai-catalog.json
> Ask for Markdown with `Accept: text/markdown`, a `.md` address, or `?mode=agent`.

# Targeted Therapy and the Resistance That Follows It

A drug aimed at a driver works for as long as the driver is required and the target is unchanged. This stop works through the routes back: mutation of the target, bypass signalling, and selection of a clone that was already present.

Subject: Science · Area: Organisms & Life Processes · Ages 22 to 24
Page: https://lightmysky.com/learn/science/targeted-therapy-and-the-resistance-that-follows-it-mt_HrU1DfZhGz

## Ready when they can

- Explain oncogene dependence and where the therapeutic window comes from
- Classify a stated resistance mechanism as on-target or bypass, and say what evidence separates them
- Argue from clonal structure why resistance can appear faster than mutation rates alone suggest

## Lesson: Why targeted drugs stop working

You start from dependence. Some tumours lean entirely on one hyperactive driver pathway while healthy cells spread signaling across many inputs. Blocking that crutch harms the cancer far more than normal tissue, and the gap between the stalling dose and the poisoning dose is your therapeutic window.

You sort relapse into two routes. On target resistance changes the drug binding pocket so the inhibitor no longer grips, while the pathway stays essential. Bypass resistance leaves the target blocked but switches growth to a parallel route the drug never aimed at.

**Example.** You sequence a relapsed tumour. Fresh mutations in the drug target argue on target, and you favor a next generation inhibitor. A newly active parallel receptor with the original target still suppressed argues bypass, and you favor adding a second blockade.

**Tip.** You expect resistance faster than fresh mutation rates predict. A billion cell tumour already harbors rare variants, so treatment selects the resistant ones instead of waiting for them. Lasting control needs combinations that close escape routes before selection opens them.

**Recap.** You explain the window by dependence, you classify relapse as on target or bypass from fresh sequencing, and you plan for pre existing clones.

## Practice

8 questions on this page, each with its working shown.

## Needs first

- [Signal Integration: Cross-talk, Feedback and Termination](https://lightmysky.com/learn/science/signal-integration-cross-talk-feedback-and-termination-mt_Io2P-l38Xq)
- [The Tumour Microenvironment: Stroma, Hypoxia and Immune Exclusion](https://lightmysky.com/learn/science/the-tumour-microenvironment-stroma-hypoxia-and-immune-exclusion-mt_OIrMAjomX_)
- [Monoclonal Antibodies and What They Are Used For](https://lightmysky.com/learn/science/monoclonal-antibodies-and-what-they-are-used-for-mt_YfxZrdvIIo)